Overall, DoE is a valuable approach to improving the quality and efficacy of the final product, streamlining the process, and ...

A new study has confirmed that the rate of colorectal cancer is rising in younger adults around the world, with England among ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

As a result of the preliminary STOMP data – which gave the chances of a positive outcome from the study at less than 1% – the ...

As the current system falters under the weight of inefficient processes and systemic barriers, this is not just a matter of ...

Agamree was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in January and has a pre-discount list ...

"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

Sports marketing offers healthcare brands an alternative channel to reach their audiences and align with the strong brand ...

Launching a new pharmaceutical product is a high-stakes endeavour. Over the past decade, nearly 40% of launches have fallen ...

Mulvany – who left BenevolentAI when it listed on the Amsterdam stock exchange in 2022 and retains a sizeable stake in the ...

The result of the NEXUS trial means that the two companies can now press on with their plan to refile for EU approval of the ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover ...